Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 18,500 shares, a growth of 203.3% from the December 31st total of 6,100 shares. Based on an average daily trading volume, of 10,700 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.2% of the company's stock are short sold.

Armata Pharmaceuticals Trading Up 1.9 %

Shares of NYSEAMERICAN ARMP traded up $0.04 during trading hours on Wednesday, reaching $2.12. 792 shares of the stock traded hands, compared to its average volume of 10,719. The stock has a market cap of $76.70 million, a price-to-earnings ratio of -1.29 and a beta of 0.85. Armata Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $4.48.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research note on Thursday, December 19th.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.